Xcout IntelStructure Therapeutics Inc.
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
Subscribe to see Structure Therapeutics Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Structure Therapeutics Inc. at a glance
Structure Therapeutics Inc. is a biotech company headquartered in South San Francisco, United States. It is publicly listed (GPCR) with a market capitalisation of $2B. Xcout tracks 17 named people at Structure Therapeutics Inc., including Raymond C Stevens (Chief Executive Officer & Director). Xcout recorded 1 job posting from Structure Therapeutics Inc. in the last 90 days.
Structure Therapeutics Inc. leadership
- Raymond C StevensChief Executive Officer & Director
- Matthew LangCOO & General Counsel
- Yingli MaChief Technology Officer
- Xichen LinChief Scientific Officer & GM of Structure Shanghai
- Blai CollChief Medical Officer
- Jun S. YoonCo- Founder, Chief Financial Officer & Secretary
11 more named people on record for Structure Therapeutics Inc., with roles, board committees and tenure — see the full roster →
Hiring at Structure Therapeutics Inc.
Xcout recorded 1 job posting from Structure Therapeutics Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Structure Therapeutics Inc.'s hiring signals →
Structure Therapeutics Inc. competitors
A few of Structure Therapeutics Inc.'s closest competitors — see the full list of competitors and alternatives →
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
Expedition Therapeutics is a clinical-stage biotechnology company headquartered in San Francisco, California, developing novel oral small molecule therapies for serious inflammatory and respiratory diseases.
Spiral Therapeutics Inc. is a clinical-stage pharmaceutical company based in South San Francisco, California, focused on delivering targeted therapies for inner ear conditions.
Akero Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company is dedicated to developing transformational therapies for metabolic dysfunction-associated steatohepatitis and other metabolic diseases.
Get Structure Therapeutics Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Structure Therapeutics Inc. in Xcout Intel
- 17 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access